Rite Aid stock plunges after Deutsche Bank cuts target to $1, warns of a ‘dramatic negative inflection point’

Fiscal 2023 guidance appears ‘unattainable,’ creating a risk that the drugstore chain’s equity may have no value

Shares of Rite Aid Corp. plunged toward a 2 1/2-year low Thursday after Deutsche Bank analyst George Hill issued a dire warning that the drugstore chain’s equity could be worthless.

Hill cut his rating on Rite Aid’s stock RAD, -23.40% to sell, after being on hold for the past two years. He slashed his price target to $1 from $16, with the new target implying a downside of 88% from Wednesday’s closing price of $8.44.

The stock sank 24.4% in morning trading, putting them on track for the lowest close since August 2019.

Related:  Dow futures fall 200 points as the British pound hits record low against the dollar

Hill said that when Rite Aid reports fiscal fourth-quarter results on April 14, the “key investor focus” will be on fiscal 2023 guidance for earnings before interest, taxes, depreciation, and amortization (Ebitda). In December, the company had said it expected 2023 adjusted Ebitda that was “significantly above” $430 million.

Hill said the reason the 2023 outlook is so important is that the company needs to generate about $400 million to $450 million in annual adjusted Ebitda to continue as an operating company.

“At a number below $400 million, the equity arguably has no value as the company is not in a position to generate real returns to shareholders,” Hill wrote in a note to clients. “Unfortunately, we believe COVID has hastened the decline of the retail pharmacy segment and we see the potential for a dramatic negative inflection point for [Rite Aid] shares as this preliminary F2023 outlook seems to be unattainable.”

Related:  Twitter Bots Exposed

Rite Aid is expected to report an adjusted loss of 49 cents per share on revenue of $5.21 billion for the quarter through February, according to a FactSet survey of analysts, after a loss of 78 cents a share on revenue of $5.92 billion in the same period a year ago.

For fiscal 2023, the FactSet consensus is for a per-share loss of 48 cents and revenue of $21.45 billion. Hill’s estimate for 2023 adjusted Ebitda is $377 million, which could cause investors to question the company’s ability to sustain itself as a going concern.

The stock has plummeted 56.5% year to date, while shares of rival CVS Health Corp. CVS, 1.22% have eased 0.9% and the S&P 500 index SPX, -0.44% has slipped 6.2%.

Related:  What pullback? GameStop, AMC stocks still up large despite midweek selloffs

Leave a Comment